TrialBlood2012
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.
Ravi Vij et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
114 papers cite itlatest 60 shown
this paperpooled ittrialcites it